Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

10 leading pharma executives you need to know

By Brian Buntz | April 22, 2022

10 leading pharma executives

10 leading pharma executives

Given the complexity of the pharmaceutical business and the generally slow pace of new drug development, it can be challenging to identify leading pharma executives. Compensation is not necessarily an accurate barometer of success. That said, CEOs’ annualized return over tenure as CEO over their term can hint at performance.

In addition, rating sites like Glassdoor also indicate top pharma executives’ popularity.

Here, we parsed a range of metrics, including CEOs’ approval ratings, their ability to navigate the pandemic and their firms’ stock performance over time, to identify ten leading pharma executives.

[This story is part of 2022’s Pharma 50 series of content.]

Pfizer CEO Dr. Albert Bourla, leading pharma executives

Pfizer CEO Dr. Albert Bourla, leading pharma executives [Image courtesy of Pfizer/Business Roundtable]

1. Pfizer
CEO: Dr. Albert Bourla

  • Annualized return over tenure as CEO: 6%
  • Start date: January 1, 2019
  • 2021 total compensation: $24.3 million
  • Glassdoor approval rating: 89%

Pfizer veteran Dr. Albert Bourla has worked at the company for more than 25 years, becoming CEO in January 2019. The CEO shined during the pandemic, ramping up Pfizer’s focus on innovation while investing more than $2 billion at-risk to accelerate the development of a COVID-19 vaccine with partner BioNTech. The company has also developed the most popular COVID-19 oral antiviral to date. In 2022, Pfizer anticipates generating approximately $100 billion in revenue, likely cementing its role as the largest pharma company.

Eli Lilly CEO David Ricks, leading pharma executives

Eli Lilly CEO David Ricks, leading pharma executives. [Image courtesy of Eli Lilly]

2. Eli Lilly
CEO: David A. Ricks

  • Annualized return over tenure as CEO: 31%
  • Start date: January 1, 2017
  • 2021 total compensation: $21.5 million
  • Glassdoor approval rating: 84%

Also a veteran of Eli Lilly for more than 25 years, David A. Ricks inherited the corner office in January 2017. He assumed the chair of the company’s board of directors in June 2017. As CEO, he has achieved an annualized return over tenure as CEO of 31%. As CEO of the largest pharmaceutical company based in Indiana, Ricks has advocated that the state become more competitive in attracting skilled workers. In recent years, Ricks has guided Lilly in debuting a variety of new drugs, including SARS-CoV-2 neutralizing antibodies. In 2021, the company beat its revenue target, but it fell slightly short of its earnings per share target.

West Pharmaceutics CEO Eric M. Green, leading pharma executives

West Pharmaceuticals CEO Eric M. Green, leading pharma executives [Image courtesy of West Pharmaceutical Services]

3. West Pharmaceutical Services
CEO: Eric M. Green

  • Annualized return over tenure as CEO: 36.4%
  • Start date: April 24, 2015
  • 2021 total compensation: $9.5 million
  • Glassdoor approval rating: 80%

Eric M. Green joined West Pharmaceutical Services in 2015 after serving a senior executive role at Sigma-Aldrich Corp. In recent years, Green has helped the company deliver strong sales growth. In 2021, net sales of $2.8 billion were 31.9% higher than the prior year. Green has also guided the company in investing in new digital capabilities to bolster efficiency. He’s also launched new diversity and inclusion programs.

Thermo Fisher Scientific CEO Marc Casper, leading pharma executives

Thermo Fisher Scientific CEO Marc Casper, leading pharma executives. [Image courtesy of Thermo Fisher Scientific]

4. Thermo Fisher Scientific
CEO: Marc N. Casper

  • Annualized return over tenure as CEO: 23.8%
  • Start date: October 15, 2009
  • 2020 total compensation: $26.4 million
  • Glassdoor approval rating: 90%

Having assumed the role of CEO and president in 2009, Marc N. Casper started his career as a strategy consultant at Bain & Co. After Thermo Fisher Scientific emerged as a merger in 2006, Caper was named executive vice president and president of the company’s analytical technologies business unit. In 2008, he was promoted to chief operating officer and again as CEO in 2009. Casper became chairman in 2020. Casper has overseen the company’s offerings for pharma customers, which spans from discovery, development, clinical activities and manufacturing.

Argenx CEO Tim Van Hauwermeiren, leading pharma executives

Argenx CEO Tim Van Hauwermeiren, leading pharma executives. [Image courtesy of Argenx]

5. Argenx
CEO: Tim Van Hauwermeiren

  • Annualized return over tenure as CEO: 85.3%
  • Start date: July 15, 2008
  • 2021 total compensation: €6.1 million
  • Glassdoor approval rating: Not available

The co-founder and CEO of Argenx NV, Tim Van Hauwermeiren, has more than two decades of experience in management and business development. Assuming the role of CEO in 2008 after co-founding the company, Hauwermeiren has achieved an annualized return over tenure as CEO of 85.3%. During his tenure, Hauwermeiren has overseen the recruitment of a competitive leadership team in Gent, Belgium and Boston and built a significant antibody pipeline.

Novo Nordisk CEO Lars Fruergaard Joergensen, leading pharma executives

Novo Nordisk CEO Lars Fruergaard Joergensen, leading pharma executives. [Image courtesy of Novo Nordisk]

6. Novo Nordisk
CEO: Lars Fruergaard Jørgensen

  • Annualized return over tenure as CEO: 25.2%
  • Start date: January 1, 2007
  • 2021 total compensation: DKK 29.6 million
  • Glassdoor approval rating: 95%

Joining Novo Nordisk in 1991, Lars Fruergaard Jørgensen has worked in several roles at the company, assuming the role of CEO in January 2017. In recent years, Jørgensen has worked to extend the company’s dominion to extend beyond diabetes to include obesity, hemophilia and other chronic diseases. Jørgensen has achieved an annualized return over his tenure of 25.2%.

Genmab CEO Jan G. J. van de Winkel, leading pharma executives

Genmab CEO Jan G. J. van de Winkel, leading pharma executives. [Image courtesy of Genmab]

7. Genmab
CEO: Jan G. J. van de Winkel

  • Annualized return over tenure as CEO: 41.5%
  • Start date: June 1, 2010
  • 2021 total compensation: DKK 7.9 million
  • Glassdoor approval rating: 86%

Genmab co-founder and CEO Dr. van de Winkel was appointed as president and CEO in 2010. He has more than 25 years of experience in the therapeutic antibody field. Currently, the company has six approved medicines and a differentiated pipeline with approximately 20 preclinical projects.

In 2021, the company won FDA approval for Tivdak in collaboration with Seagen.

AbbVie CEO Rick Gonzalez, leading pharma executives

AbbVie CEO Richard A. Gonzalez, leading pharma executives. [Image courtesy of AbbVie]

8. AbbVie
CEO: Richard A. Gonzalez

  • Annualized return over tenure as CEO: 18.8%
  • Start date: January 1, 2013
  • 2021 total compensation: $23.9 million
  • Glassdoor approval rating: 83%

AbbVie CEO ​​Richard A. Gonzalez had 30 years of experience at Abbott before assuming the mantle of CEO of AbbVie in 2013 when Abbott spun out the company. As CEO, Gonzalez has achieved an annualized return of close to 19%. In addition, the company achieved a robust growth rate of 23% in 2021 without debuting a major COVID-19 product.

Evotec CEO Dr. Werner Lanthaler, leading pharma executives

Evotec CEO Dr. Werner Lanthaler, leading pharma executives. [Image courtesy of Evotec]

9. Evotec
CEO: Dr. Werner Lanthaler

  • Annualized return over tenure as CEO: 38.8%
  • Start date: March 6, 2009
  • 2021 total compensation: $4.0 million
  • Glassdoor approval rating: 84%

Evotec CEO Dr. Werner Lanthaler began his tenure as CEO in 2009. Lanthaler has overseen the company’s evolution from a venture-backed biotech company into an international vaccine company. In addition, Lanthaler has led a string of acquisitions, strategic partnerships and the company’s initial public offering in 2005.

Sartorius Stedim Biotech CEO Joachim Kreuzburg, leading pharma executives

Sartorius Stedim Biotech CEO Joachim Kreuzburg, leading pharma executives. [Image courtesy of Sartorius AG]

10. Sartorius Stedim Biotech
CEO: Joachim Kreuzburg

  • Annualized return over tenure as CEO: 33.5%
  • Start date: May 1, 2003 
  • 2021 total compensation: €2.0 million
  • Glassdoor approval rating: 86%

Sartorius Stedim Biotech CEO Joachim Kreuzburg assumed leadership of the company in 2007. He also is the CEO and executive for labor relations at the firm’s parent, Sartorius AG. Kreuzburg has also served as the chairman of the executive board of Sartorius AG since 2005. Kreuzburg also is a member of the Supervisory Board of Carl Zeiss AG.


Filed Under: Drug Discovery and Development
Tagged With: AbbVie, Argenx, Eli Lilly, Evotec, Genmab, leadership, Novo Nordisk, Pfizer, Pharma 50, pharma execs, pharma executive, Sartorius Stedim Biotech, Thermo Fisher Scientific, West Pharmaceutical Services
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE